Related Experiment Video

Updated: Aug 16, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

[Beneficial neurohormonal profiles of beta-blockades in chronic left heart failure]

Fang Wang1, Zhi-min Xu, Li Wang

  • 1Key Laboratary of Cardiovascular Drugs, Cardiovascular Institute and Fuwai Heart Hospital, Peking Union Medical College, Chinese Academe of Medical Sciences, Beijing 100037, China.

Zhonghua Nei Ke Za Zhi
|August 6, 2005
PubMed

Insights

Beta-blockers significantly reduced N-terminal pro-brain natriuretic peptide (NT-proBNP) levels in chronic heart failure patients, improving left ventricular function. Renin-angiotensin-aldosterone system markers showed no significant changes.

Area of Science:

  • Cardiology
  • Pharmacology
  • Biochemistry

Background:

  • Chronic heart failure (CHF) is characterized by neurohormonal imbalances.
  • Assessing the impact of beta-blockers on these neurohormonal factors is crucial for understanding treatment efficacy.

Purpose of the Study:

  • To evaluate the effects of beta-blockers (bisoprolol and carvedilol) on neurohormonal factors in patients with CHF.
  • To assess the relationship between neurohormonal markers, left ventricular ejection fraction (LVEF), and clinical outcomes.

Main Methods:

  • 44 CHF patients (LVEF ≤ 40%) received conventional therapy plus either bisoprolol or carvedilol for 7 months.
  • Plasma levels of renin activity (PRA), angiotensin II (Ang II), aldosterone (Ald), and N-terminal pro-brain natriuretic peptide (NT-proBNP) were measured.
  • Left ventricular ejection fraction (LVEF) was assessed at baseline and 7 months.

Main Results:

  • NT-proBNP levels decreased significantly after beta-blocker therapy, while PRA, Ang II, and Ald levels remained unchanged.
  • Higher baseline NT-proBNP levels correlated with lower LVEF.
  • Post-therapy LVEF improvement was associated with decreased NT-proBNP levels.

Conclusions:

  • NT-proBNP is a sensitive marker for CHF severity and prognosis, more so than PRA, Ang II, and Ald.
  • Beta-blocker therapy in CHF reduces NT-proBNP and improves LVEF, without significantly affecting the renin-angiotensin-aldosterone system.
Abstract

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...